Novavax

Novavax company information, Employees & Contact Information

Explore related pages

Related company profiles:

We’re focused on using our proven vaccine technology to protect health by developing our R&D assets and establishing partnerships. We stand strong against infectious diseases and viral threats—our science grounds us, our technology pushes us forward, our commitment inspires us to achieve our mission of ensuring broad access to our vaccines. It’s more than our job. It’s our passion. Our Novavax Social Community Guidelines: https://www.novavax.com/social-media-community-guidelines

Company Details

Employees
1.07K
Founded
-
Address
700 Quince Orchard Rd, Gaithersburg,maryland 20878,united States
Phone
(240) 268-2000
Email
ir****@****vax.com
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Gaithersburg, Maryland
Looking for a particular Novavax employee's phone or email?

Novavax Questions

News

Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial - Novavax Investor Relations

Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial Novavax Investor Relations

Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy - Sahm

Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy Sahm

$25M Milestone: Novavax Transfers Nuvaxovid EU Authorization to Sanofi; Eligible for Up to $350M - Stock Titan

$25M Milestone: Novavax Transfers Nuvaxovid EU Authorization to Sanofi; Eligible for Up to $350M Stock Titan

Novavax to Report Second Quarter 2025 Financial Results on August 6, 2025 - Yahoo Finance

Novavax to Report Second Quarter 2025 Financial Results on August 6, 2025 Yahoo Finance

Guided by Purpose: Reimagined Mission, Vision and Values to Power Novavax Forward - Novavax

Guided by Purpose: Reimagined Mission, Vision and Values to Power Novavax Forward Novavax

Novavax Continues to Deliver on Sanofi Partnership, Completing Nuvaxovid® EU Marketing Authorization Transfer and Triggering $25 Million Milestone Payment - PR Newswire

Novavax Continues to Deliver on Sanofi Partnership, Completing Nuvaxovid® EU Marketing Authorization Transfer and Triggering $25 Million Milestone Payment PR Newswire

Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights - Yahoo Finance

Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights Yahoo Finance

$200M Potential Deal: Novavax's Matrix-M Tech Powers Sanofi's Pandemic Flu Vaccine Development - Stock Titan

$200M Potential Deal: Novavax's Matrix-M Tech Powers Sanofi's Pandemic Flu Vaccine Development Stock Titan

Novavax Announces Progress on Sanofi Agreement - PR Newswire

Novavax Announces Progress on Sanofi Agreement PR Newswire

Novavax to Report First Quarter 2025 Financial Results on May 8, 2025 - Yahoo Finance

Novavax to Report First Quarter 2025 Financial Results on May 8, 2025 Yahoo Finance

Novavax's Nuvaxovid™ 2025-2026 Formula COVID-19 Vaccine Approved in the U.S. - PR Newswire

Novavax's Nuvaxovid™ 2025-2026 Formula COVID-19 Vaccine Approved in the U.S. PR Newswire

Novavax Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights - Yahoo Finance

Novavax Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights Yahoo Finance

U.S. FDA Approves BLA for Novavax's COVID-19 Vaccine - PR Newswire

U.S. FDA Approves BLA for Novavax's COVID-19 Vaccine PR Newswire

Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights on February 27, 2025 - Yahoo Finance

Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights on February 27, 2025 Yahoo Finance

Novavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study - PR Newswire

Novavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study PR Newswire

Nuvaxovid® Now Approved in Japan Triggering Takeda Milestone Payment - PR Newswire

Nuvaxovid® Now Approved in Japan Triggering Takeda Milestone Payment PR Newswire

Novavax Announces Convertible Debt Refinancing - PR Newswire

Novavax Announces Convertible Debt Refinancing PR Newswire

Novavax Announces Changes to Board of Directors - PR Newswire

Novavax Announces Changes to Board of Directors PR Newswire

Novavax to Participate in BofA Securities 2025 Health Care Conference - PR Newswire

Novavax to Participate in BofA Securities 2025 Health Care Conference PR Newswire

Novavax Announces Significantly Improved Terms for Collaboration and License Agreement with Takeda for Nuvaxovid® in Japan - PR Newswire

Novavax Announces Significantly Improved Terms for Collaboration and License Agreement with Takeda for Nuvaxovid® in Japan PR Newswire

Novavax Reports First Quarter 2025 Financial Results and Operational Highlights - PR Newswire

Novavax Reports First Quarter 2025 Financial Results and Operational Highlights PR Newswire

SHIELD-Utah Study Shows Novavax's COVID-19 Vaccine Induces Lower Reactogenicity Symptoms Compared to mRNA - PR Newswire

SHIELD-Utah Study Shows Novavax's COVID-19 Vaccine Induces Lower Reactogenicity Symptoms Compared to mRNA PR Newswire

Novavax Announces Sale of Czech Republic Manufacturing Site to Novo Nordisk for $200 Million - PR Newswire

Novavax Announces Sale of Czech Republic Manufacturing Site to Novo Nordisk for $200 Million PR Newswire

Novavax Initiates Phase 3 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza - PR Newswire

Novavax Initiates Phase 3 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza PR Newswire

Novavax Advances Corporate Growth Strategy Through Sanofi Partnership, Including Achievement of First $50 Million Milestone - PR Newswire

Novavax Advances Corporate Growth Strategy Through Sanofi Partnership, Including Achievement of First $50 Million Milestone PR Newswire

Novavax Announces Shipments of its COVID-19 Vaccine to European Union Member States - Novavax Investor Relations

Novavax Announces Shipments of its COVID-19 Vaccine to European Union Member States Novavax Investor Relations

Novavax and Gavi Reach Settlement on 2021 COVID-19 Vaccine Advance Purchase Agreement - Gavi, the Vaccine Alliance

Novavax and Gavi Reach Settlement on 2021 COVID-19 Vaccine Advance Purchase Agreement Gavi, the Vaccine Alliance

Åsa Manelius Named Managing Director of Novavax AB Site - PR Newswire

Åsa Manelius Named Managing Director of Novavax AB Site PR Newswire

Novavax 2024-2025 Formula COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S. - PR Newswire

Novavax 2024-2025 Formula COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S. PR Newswire

Novavax and Sanofi Announce Co-exclusive Licensing Agreement to Co-commercialize COVID-19 Vaccine and Develop Novel COVID-19-Influenza Combination Vaccines - PR Newswire

Novavax and Sanofi Announce Co-exclusive Licensing Agreement to Co-commercialize COVID-19 Vaccine and Develop Novel COVID-19-Influenza Combination Vaccines PR Newswire

Phase 3 trial of Novavax investigational COVID-19 vaccine opens - National Institutes of Health (.gov)

Phase 3 trial of Novavax investigational COVID-19 vaccine opens National Institutes of Health (.gov)

CEPI extends collaboration with Novavax to advance development and manufacture of COVID-19 vaccine - CEPI

CEPI extends collaboration with Novavax to advance development and manufacture of COVID-19 vaccine CEPI

Novavax 2023-2024 COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S. - PR Newswire

Novavax 2023-2024 COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S. PR Newswire

Novavax’s COVID-19 vaccine gets nod from WHO as FDA submission looms - Healio

Novavax’s COVID-19 vaccine gets nod from WHO as FDA submission looms Healio

Gaithersburg-Based Novavax's Updated Non-mRNA COVID-19 Vaccine Now Available at Costco, CVS, Giant, and Other Major Pharmacies - The MoCo Show -

Gaithersburg-Based Novavax's Updated Non-mRNA COVID-19 Vaccine Now Available at Costco, CVS, Giant, and Other Major Pharmacies The MoCo Show -

Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in the Philippines - PR Newswire

Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in the Philippines PR Newswire

Novavax and Israel Announce Advance Purchase Agreement for Supply of COVID-19 Vaccine - PR Newswire

Novavax and Israel Announce Advance Purchase Agreement for Supply of COVID-19 Vaccine PR Newswire

Novavax Announces Proposed $125 Million Public Offering of Common Stock - The Korea Herald

Novavax Announces Proposed $125 Million Public Offering of Common Stock The Korea Herald

Novavax Announces Submission of Biologics License Application in South Korea for Approval of NVX-CoV2373 - The Korea Herald

Novavax Announces Submission of Biologics License Application in South Korea for Approval of NVX-CoV2373 The Korea Herald

Novavax Announces Positive Top-Line Data from Phase 2 RSV F-Protein Vaccine Clinical Trial in Older Adults - MultiVu

Novavax Announces Positive Top-Line Data from Phase 2 RSV F-Protein Vaccine Clinical Trial in Older Adults MultiVu

Top Novavax Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant